| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CEO
1 company
Brian Lian is President & CEO at VKTX. Brian Lian's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $67.1M at current prices.
Historically, Brian Lian's trades have earned a middling insider score of 54/100 across 20 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -30.7%.
The VKTX filings lean toward selling, a net 2,079,920 shares.
Brian Lian has 37 Form 4 filings on record from May 2015 to July 2026, all as President & CEO at Viking Therapeutics (VKTX), 2015–2026.
The 111 reported transactions were 36 open-market sales, 25 stock awards, 21 tax withholdings and 14 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 18 sales worth about $74.7M.
The largest open-market sale was 216,130 shares of VKTX at an average $70.83 on September 20, 2024, about $15.3M. Twelve months later VKTX was down 64%.
7 of the 18 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 11 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 148,517 | $33.32 | $4,947,888.41 | -5.5% | -25.5% | - | |
| Jan 5, 2026 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 233,409 | $32.96 | $7,692,120.64 | -8.5% | +5.6% | - | |
| Oct 28, 2025 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 38,989 | $35.01 | $1,364,923.01 | -1.6% | -9.2% | -27.4% | |
| Jul 3, 2025 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 26,889 | $27.80 | $747,632.51 | -1.1% | -2.9% | +32.8% | |
| Jan 6, 2025 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 194,490 | $42.75 | $8,313,601.16 | -7.6% | -50.0% | -24.1% | |
| Sep 20, 2024 | VKTX Viking Therapeutics, Inc. | President & CEO | Sale+OE10b5-1 | 216,130 | $70.83 | $15,308,552.90 | -8.6% | -41.1% | -64.0% | |
| Aug 21, 2024 | VKTX Viking Therapeutics, Inc. | President & CEO | Sale+OE10b5-1 | 1,000 | $69.90 | $69,900.00 | - | -20.5% | -60.4% | |
| Aug 19, 2024 | VKTX Viking Therapeutics, Inc. | President & CEO | Sale+OE10b5-1 | 112,870 | $65.80 | $7,426,507.68 | -4.6% | -26.3% | -63.4% | |
| Jul 30, 2024 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell | 115,859 | $57.58 | $6,670,604.02 | -4.7% | +31.8% | -40.4% | |
| Feb 9, 2024 | VKTX Viking Therapeutics, Inc. | President & CEO | Sell10b5-1 | 45,000 | $29.90 | $1,345,500.00 | -2.1% | +162.3% | +6.5% |